An overview of extended-spectrum beta-lactamases in veterinary medicine and their public health consequences

Diego Borin Nóbrega, Marcelo Brocchi

Department of Genetics, Evolution, and Bioagents, University of Campinas, Campinas, Brazil

Abstract

Serious human and animal infections caused by bacteria are usually treated with beta-lactams. Extended-spectrum beta-lactamases (ESBLs) constitute the most clinically and economically important enzymes that are able to hydrolyze and inactivate beta-lactam antibiotics in veterinary medicine. The spread of ESBLs represents a serious threat to healthcare systems, drastically undermining therapeutic options. The relationship between drug usage and the emergence of resistance has been extensively reported. Nevertheless, the use of antimicrobials in veterinary medicine and the emergence of ESBLs in animals remains a matter of debate. Moreover, there is still controversy about whether antibiotic usage in farm animals poses a potential public health risk. This review will (i) deal with aspects related to the presence of ESBLs in veterinary medicine, (ii) its link with human medicine, and (iii) discuss strategies to be implemented to preserve antimicrobial effectiveness. New insights relative to old questions concerning antimicrobial use in domestic animals are also presented.

Key words: antimicrobial therapy; drug resistance; ESBLs; veterinary medicine.


(Received 13 January 2014 – Accepted 04 April 2014)

Copyright © 2014 Nóbrega et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Extended-spectrum beta-lactamases: introduction

Antimicrobial therapy in veterinary medicine has several applications. Beta-lactams constitute one of the most important groups of antimicrobial agents in veterinary medicine and are the therapy of choice for some well-established practices, including dry cow therapy in dairy cows and weaning therapy in pigs.

Extended-spectrum beta-lactamases (ESBLs) are the most clinically and economically important enzymes that are able to hydrolyze and inactivate beta-lactam antibiotics in veterinary medicine. On genetic grounds, the presence of ESBLs is associated with resistance to other classes of non-beta-lactam antibiotics, including fluoroquinolones, aminoglycosides, and trimethoprim-sulfamethoxazole. In this context, infections caused by these bacteria have limited therapeutic options.

Due to their increasing prevalence, ESBLs quickly became a great burden on human medicine [1,2]. Within the last decade, attention was drawn to animal sources, as there was a rapid increase of infections due to ESBL-producing bacteria. Nowadays, animals live in much closer contact with human populations, and several antimicrobial agents are shared between humans and animals. Moreover, several Gram-negative bacteria that clinically and economically impact veterinary medicine may cause infections in humans.

The increasing prevalence of ESBL-producing bacteria, the growing concern about bacterial resistance, and the lack of biosecurity in the livestock industry of underdeveloped countries were responsible for a substantial rise in the reporting of ESBLs in veterinary medicine. The number of publications referring to ESBL-producing bacteria in veterinary medicine has exponentially increased. ESBL-producing bacteria have already been isolated from bovine mastitis [3], meat products [4], broiler chickens’ feces and livers [5], horses [6], swine [7], dairy calves, cows, and dairy farm environment [8,9]. As for companion animals, ESBL-producing bacteria have been found in urinary tracts of dogs and cats [10], wound sites, and preputial discharge of companion animals [11], cases of cholangio-hepatitis in dogs [12], and in dog feces [13]. In wild animals, ESBLs have been detected in fecal samples from birds of prey [14], urban brown rats [15], and in seagulls [16].

In particular, numerous studies have underlined that the impact of animal ESBL enzymes on human medicine remains to be determined. Molecular
epidemiology methods are used to classify the worldwide distribution of ESBL-producing isolates and to describe their underlying resistance mechanisms. General advances in molecular biology methods, with the recent advent of the analysis of clonality using multilocus sequence typing (MLST) in particular, have offered new insights into old issues. This review intends to summarize aspects related to the presence of ESBLs in veterinary medicine and to describe how they affect human health. The impact of antimicrobial use in veterinary medicine and the implementation of strategies to control the use of antimicrobials and preserve their effectiveness are also discussed.

**ESBL-positive isolates: a threat to animal and human health**

ESBL-producing bacteria have been isolated from healthy animals [17-19], and can be responsible for self-limiting episodes of gastroenteritis. In this context, is it possible to determine how ESBLs impacts human and veterinary medicine?

Exposure to MDR (multidrug-resistant) bacteria enhances the risk of colonization by these pathogens is enhanced. For instance, travelling to specific countries can be a risk factor for the acquisition of ESBL-producing Enterobacteriaceae among the fecal flora. Several infections, such as sepsis and urinary tract infections caused by ESBL-producing bacteria, assumed to be caused by the patient’s own fecal flora. Overall, this information should be taken into serious consideration, because colonization by MDR bacteria represents a first step towards untreatable infections [20].

Serious human and animal infections caused by bacteria are usually treated with extended-spectrum cephalosporins and other beta-lactams. Therefore, the spread of ESBLs represents a serious threat to healthcare systems. For instance, the risk of a fatal outcome is twofold higher among patients with sepsis caused by ESBL-producing bacteria than among patients infected by susceptible Enterobacteriaceae [21]. Particularly, children and the elderly are susceptible to infections caused by Enterobacteriaceae. For severe, life-threatening infections, antimicrobial therapy can be life saving [22].

The spread of ESBLs undermines therapeutic options. Life-threatening pathogens are now resistant to beta-lactams. To overcome infections caused by ESBL-producing bacteria, it is crucial to turn to more potent drugs. Nevertheless, the discovery of new and more effective drugs has experienced a significant slowing down in the last two decades. In this scenario, it is vital to preserve the effectiveness of the currently available antibiotics.

Hence, it is unquestionable that ESBL-producing bacteria are a threat to human and animal health. Exposure to MDR pathogens may culminate in colonization and possible infection that is not responsive to treatment, in humans and animals alike.

**Antimicrobial therapy and emergence of ESBLs in veterinary medicine**

Since the advent of antibiotics in veterinary medicine, the use of beta-lactams has exponentially increased. The massive and indiscriminate use of these antibiotics and their link with a worldwide increase of infections due to ESBL-producing bacteria has drawn the attention of the scientific community. Despite extensive reports on the association between drug usage and resistance [23], the use of antimicrobials in veterinary medicine and the emergence of ESBLs in animals remains a matter of intense debate.

A significant body of the scientific community supports the link between MDR organisms and antimicrobial use in veterinary medicine [24]. Nevertheless, distinct points of view have also been reported. For instance, ESBL-producing bacteria are isolated from broiler farms that do not apply cephalosporin treatments [5,25]. In addition, cefotiofur therapy does not seem to increase the amount of resistant bacteria in the intestinal tract of dairy cows [26]. In this scenario, the administration of systemic drugs can, but not necessarily will, collaborate with the emergence and maintenance of antimicrobial resistance genes.

In contrast, cephalosporin therapies seem to increase the occurrence of ESBL-producing bacteria [27,28]. In agreement with other researchers, Damborg et al. found that hospitalization and broad-spectrum antimicrobial prophylaxis culminate in fecal shedding of ESBL-producing bacteria in horses [29]. Moreover, antimicrobial resistance may be lower in bacterial isolates from subclinical mastitis cases exactly because these cases are less frequently treated in relation to clinical mastitis [30], although this hypothesis needs to be validated [31].

It is recognized that antimicrobial therapies are linked with the selection of ESBL-producing bacteria. Smith et al. demonstrated that antimicrobial therapies may hasten the emergence of antimicrobial resistance that would, otherwise, be delayed [32]. Theoretically, even if application of antimicrobials had never
occurred, resistance genes would have accumulated random DNA mutations that would have led to loss of function. In addition, organisms possessing resistance plasmids could have a disadvantage under natural conditions. For instance, several protocols of plasmid curing rely on temperature variation processes. Under stress, bacteria may “cure” the unnecessary resistance plasmid. Notably, the Clinical Laboratory and Standard Institute (CLSI) has recommended that quality control cultures kept under refrigeration temperature should be prepared on a weekly’s basis. Indeed, unexplained results have suggested that the inherent susceptibility of the organism might change along time.

Overall, studies support a strong link between drug usage and the emergence of resistance. This connection is more evident in two distinct scenarios: (1) unsuccessful, indiscriminate, and poorly conducted therapies, and (2) off-label use of antibiotics. The latter scenario has been a consequence of the implementation of antibiotics for non-authorized indications [24]. Indiscriminate and poorly conducted therapies are certainly the main reason for the emergence and amplification of drug resistance cases in veterinary medicine [3]. In contrast, in dairy herds, there is very little evidence supporting an increase in antimicrobial resistance due to well-conducted mastitis treatments [33]. Under these circumstances, antimicrobial therapy in veterinary medicine has a minor impact on the emergence of ESBLs.

Antimicrobial therapy can be a risk factor for the emergence of ESBLs for two reasons. First, in undeveloped industries, the absence of protocols for drug administration and storage, failure to establish on-farm treatment records and to verify the compliance of treatment protocols, poor biosecurity, and off-label use of antibiotics are clearly linked to the increased prevalence of ESBL-producing isolates. These overall practices should be discouraged. For instance, the management system accounts for the prevalence of ESBL-producing *E. coli* in cattle [34]. Moreover, intensive poultry breeding and high concentrations of animals in the same premise favors the transmission of resistant bacteria among animals [35]. In addition, systemic treatments result in elimination of antimicrobial residues through feces, urine, and milk [36]. This scenario supports the selection and transfer of ESBL genes outside the animal level.

The second reason is that different efforts at national levels interfere directly with drug resistance. Guidelines for alternative therapies, monitoring programs, and development of preventive medicine may limit the spread of ESBLs in veterinary medicine. Together, these strategies could certainly reduce the impact of several MDR microorganisms on animal health.

**Veterinary antimicrobial therapies and ESBL emergence in human medicine**

The overall quantity of antimicrobials used in the modern livestock industry and their link with human medicine have drawn considerable global attention. Nevertheless, there is still controversy about whether antibiotic usage in farm animals will become a potential public health risk [37].

Points of view that differ from the common belief that antimicrobial therapies in animals may influence human health have also been reported. Phillips *et al.* reviewed several aspects of antimicrobial therapies in veterinary medicine; they concluded that most of the resistance problems detected in humans originated from human medicine [37]. Animal bacteria do not persist in human intestinal microflora mainly due to lack of host specificity [38]. In this context, ESBL-producing *E. coli* isolated from animals can be different from clinical isolates [39]. Moreover, mathematical models of antimicrobial usage in the farm industry and the emergence of drug resistance in humans strongly suggests that infection control and prudent medical antimicrobial usage rather than elimination of the use of antimicrobials in animals will more likely reduce the prevalence of antimicrobial resistance in hospitals. Medical antimicrobial therapies are largely responsible for human-to-human transmission. Hence, eliminating the use of antimicrobial in livestock animals would have minor effects on the prevalence of antimicrobial resistance in clinical isolates [32].

In contrast, there is strong evidence suggesting that the use of antimicrobials in livestock animals has potential effects on humans [40]. Interspecies transfer between animals and humans has been well documented [41]. Similar gene cassettes are commonly found in animals and in clinical isolates [17,42]. Moreover, ESBL-producing *E. coli* isolated from brown rats and humans share genetic similarities [15]. Notably, an ESBL-positive virulent *E. coli* isolated from a rat in Berlin was affiliated to ST95, which represents one of the key extraintestinal pathogenic *E. coli* in humans [43]. With regard to the bacteria specificity, colonization does not seem to be essential for the transfer of resistance traits. Horizontal transfer may take place as resistant bacteria are
passing through the intestinal tract. Hence, enterococci from animals may enter the hospital environment and eventually transfer resistance genes to well-established isolates [44].

Overall, antimicrobial usage in the farm industry supports the emergence of antimicrobial resistance in clinical isolates through two distinct processes. First, it may increase the occurrence of antimicrobial resistance in zoonotic pathogens. Antimicrobial usage in veterinary medicine may hasten the appearance of MDR pathogens, decreasing the efficacy of antimicrobials in human infections [32]. Second, it may ease the spread of MDR bacteria that exchange genetic material with human commensal bacteria. ESBL genes may undergo horizontal transfer. Highly mobile genetic elements, such as integrons and transposons, may promote lateral transfer among different bacterial species. These isolates are able to transfer resistance traits to others [45,46] and cause opportunistic infections. For instance, treatments and the use of growth promoters in farms might select resistant Salmonella spp. isolates that could, under appropriate circumstances, reach food products [47,48]. Although bacteria like Salmonella spp. can be killed during the cooking process, in raw or undercooked chicken meat, the bacteria could survive and enter the human food chain, or exchange genetic material with human pathogenic bacteria. As discussed previously in this review, colonization with ESBL-producing bacteria represents the first step towards untreatable infections. In this context, antimicrobial treatments in animals and contaminated meat products pose a serious threat to human health [35].

Therefore, the dissemination of common resistance traits in both animals and humans provides evidence that animals may act as reservoirs of ESBLs. Furthermore, if humans and animals share similar resistance traits, any unsuccessful antimicrobial therapy in one represents a risk to the other, due to the clear relationship between drug usage and the emergence of drug resistance. Hence, control measures should be encouraged for veterinary and human medicine alike.

**How do we prevent the increase of ESBLs from animal origin in human medicine?**

Several sources of ESBLs in veterinary medicine have been reported. Samples from broiler chickens collected at slaughterhouses [49], pets in community and nursing homes [17,46], soil and fecal samples [50,51], and even flies [52] were found to harbor ESBL-positive isolates. As discussed earlier, these isolates may act as ESBL reservoirs in the community. Strategies to assure the preservation of human health should decrease the opportunities for selection of drug-resistant organisms in animals [24]. A multifaceted approach to limit contamination and the spread of ESBLs of animal origin in humans should be encouraged.

It is crucial to identify risk factors associated with the emergence of ESBLs of animal origin. Veterinary medicine has made several advances, which has culminated in the eradication of diseases, gains in productivity, and improvements in public health, in all of which antimicrobial therapy played an important role. However, antimicrobial therapy has long been recognized as the main risk factor for the emergence of drug resistance and is the main reason for the rise of ESBL-producing isolates in animals. A control plan for ESBLs in veterinary medicine must regulate antimicrobial usage in animals. To pursue this strategic point, important antimicrobials for humans should be drastically limited in veterinary medicine. Interestingly, the best time to regulate antimicrobials in veterinary medicine is before the onset of clinically resistant isolates [32]. Zoonotic bacteria would be sensitive to antimicrobials frequently used in human medicine, and only when resistant isolates were considered disseminated should veterinary formulations of the same principles be allowed. Despite being polemic, this strategy would preserve the efficacy of antimicrobials.

Moreover, guidelines regarding the prudent use of antimicrobials should be released. Some well-known strategies can decrease the selection of ESBLs in animals and, consequently, in humans. For instance, the elimination of unnecessary antimicrobial treatments for viral infections, the use of narrow-spectrum antibiotics, and the banning of antibiotic use as a growth promoter are strategies that must be implemented [24]. In addition, alternatives for empirical antimicrobial treatment are currently available or under development and they should be taken into consideration. Probiotics, vaccines, and alternative management systems are known to reduce the number of drug resistance cases in animals [53,54].

Furthermore, the use of distinct antimicrobials classes in human and veterinary medicine is another efficient approach. Veterinarians must be instructed to prescribe appropriate antimicrobials, to ensure their judicious use, and to protect antibiotics that are critically important to humans. National government organizations should work with veterinarians towards a plan of action against ESBLs. These overall
strategies are effective in preventing the spread of animal ESBLs in the community.

In addition, initiatives ought to be encouraged at a global level, starting with worldwide epidemiologic studies focusing in comparisons between countries that adopt distinct antimicrobial policies. Standardized studies must be performed by several individual research groups and results should be compared. In this context, distinct directives could be evaluated and recommended to specific scenarios. Joint surveillance programs, such as the Canadian Integrated Program for Antimicrobial Resistance Surveillance, must be promoted at a global level. ESBL in veterinary medicine is a global challenge, and individual approaches are not enough to deal with this matter.

Hence, a multifaceted approach is required to both control antimicrobial usage and preserve its effectiveness, with collaboration between human and veterinary medicine [55]. Researchers, official institutions, and professionals should synergistically work on strategies to prevent the emergence and spread of ESBLs in humans and animals. The specific impact of ESBLs in animals cannot be understated.

Overall, the scientific community is clearly worried about the increase of the prevalence of ESBLs producing coliforms in livestock and in companion animals. Several topics discussed in this review can be extrapolated to other antimicrobial agents. We stress the need for global epidemiologic studies in order to prevent an alarming situation. Indeed, infections due to MDR isolates may lead to severe clinical outcomes for humans and animals alike.

Conclusions

Antimicrobial therapy in veterinary medicine was indubitably responsible for remarkable gains in productivity, leading to eradication of diseases and improvements in animal health. In contrast, the indiscriminate use of antibiotics has led to an increase of ESBLs in animals. More intriguingly, there is evidence suggesting that animals may act as reservoirs of these resistance determinants for humans. In this context, animal ESBL-producing isolates are a threat to both human and animal health. Therefore, it is of primary importance to implement a multifaceted approach to control antimicrobial usage. Global epidemiologic studies should be encouraged in order to preserve antimicrobial effectiveness in both human and veterinary medicine.

References


Nóbrega et al. – ESBLs in veterinary medicine and public health


958


**Corresponding author**

Diego Borin Nóbrega, Department of Genetics, Evolution, and Bioagents, Institute of Biology, University of Campinas, (UNICAMP), Monteiro Lobato Street, 255. CEP 13083-862, Barão Geraldo District, Campinas, Brazil

Phone: +55 19) 35216274
Fax: +55 19 35216185
Email: diegoborin@yahoo.com.

**Conflict of interests:** No conflict of interests is declared.